CytoNiche Biotech

CytoNiche Biotech Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CytoNiche Biotech, Biotechnology company, 1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH, Singapore.

CytoNiche™ revolutionizes CGT manufacturing with 3D FloTrix™ technology, offering GMP-grade dissolvable microcarriers, serum-free media for MSCs, and GMP-compliant equipment to support expansion, harvesting, processing, and filling.

19/06/2026

A day in the life of a cell culture specialist

People often imagine science as a single breakthrough moment. In reality, it's built on hundreds of small, precise steps repeated every day.

From cell sampling and counting to harvesting cells from microcarriers, washing, and sealing, each process requires care, consistency, and attention to detail.

Working with living cells is both exciting and humbling—because cells don't always behave exactly as planned. Every day brings new observations, challenges, and opportunities to learn.

A small glimpse into life behind the scenes in cell manufacturing.

17/06/2026

Is your technology on China’s Clinical Research Filing List?

Under Decree No. 818, inclusion on this list is the first step towards entering the clinical research pathway for innovative biomedical technologies. But what exactly is covered?

In our latest video, we break down the five major fields and 21 subcategories included in Version 1 of the filing list, covering:

🔹 Gene Therapy
🔹 Cell & Cell-Derived Therapies (including stem cells, CAR-T, NK cells, exosomes and EVs)
🔹 Tissue & Organ Therapies
🔹 Microbial Therapies
🔹 Brain-Computer Interface Technologies

We also discuss an important distinction: inclusion in the filing list enables clinical research, but it does not automatically determine the future commercialisation pathway.

If you're developing next-generation therapies or advanced biomedical technologies in China, understanding where your technology fits is essential.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

15/06/2026

What happens to existing IIT projects under China’s Decree No. 818?

Many organisations are asking whether data generated through investigator-initiated trials (IITs) can still support future translational applications or IND submissions.

The answer depends on more than clinical outcomes. Process comparability, data traceability, and manufacturing consistency will play a critical role in determining whether existing data remains valuable.

In this video, we explore:
• The relationship between IITs and translational application
• Why process comparability matters
• Risks associated with manual workflows
• How bridging studies can support the transition from IIT to IND

As regulatory expectations continue to evolve, early assessment and preparation can help ensure your data remains fit for future use.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

12/06/2026

As China advances the implementation of Decree No. 818, many leading hospitals are facing an important question:

How can they effectively fulfil their "primary responsibility" while maintaining efficiency, quality, and sustainability?

The regulation places full responsibility for the cell preparation process on Class A tertiary hospitals. While the objective is clear, the operational realities can be challenging:
🔹 Limited facility space
🔹 Manual processes and contamination risks
🔹 Long-term data retention and traceability requirements
🔹 Rising labour and operational costs

In this video, we explore how 3D automated cell culture technologies can help address these challenges by reducing footprint, improving consistency, enabling digital traceability, and lowering operational burden.

Compliance should not be viewed solely as a regulatory requirement—it can also be an opportunity to build more efficient and scalable cell therapy workflows.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

10/06/2026

Should your therapy follow the Technology Path or the Drug Path?

While both pathways aim to accelerate patient access to innovative therapies, they are designed for fundamentally different types of products. Choosing the wrong path can lead to significant challenges later in development, making early regulatory strategy more important than ever.

In this video, we explore the key differences between China's dual-track framework for cell therapy, the considerations behind pathway selection, and why process standardisation, traceability, and compliance planning should begin from day one.

As the CGT industry continues to evolve, successful commercialisation will depend not only on scientific innovation, but also on aligning development strategies with the appropriate regulatory pathway from the very beginning.

Watch the full video to learn more about how China's evolving regulatory landscape may shape the future of cell therapy development.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html
🔔 Subscribe to our channel for more insights into next-generation cell therapy and biotech innovation.

08/06/2026

What does it take for Cell & Gene Therapy to move from scientific promise to widespread patient access across Southeast Asia?

Following his participation in the High DecaGiga Cell Manufacturing Masterclass, we sat down with Dr Saranyoo Ponnikorn, Co-Founder of Bioflirt Labs, to discuss the evolving CGT landscape across the region.

Drawing from his experience in the industry, Dr Saranyoo shared valuable insights on regulatory development, manufacturing readiness, commercialisation pathways, and the opportunities that lie ahead for emerging CGT markets. The conversation also explored how different countries are approaching innovation, capacity building, and policy development to support the growth of advanced therapies.

Reflecting on the masterclass, Dr Saranyoo highlighted the value of practical, hands-on learning and was particularly impressed by the user-friendly operation of CytoNiche's 3D FloTrix™ vivaEXO Exosome Harvesting System, noting its simplicity compared with conventional solutions.

As the CGT ecosystem continues to mature, meaningful dialogue and cross-border collaboration will be essential in shaping a more scalable, accessible, and sustainable future for advanced therapies.

A big thank you to Dr Saranyoo for sharing his perspectives and contributing to the conversation.

03/06/2026

Scalable manufacturing. Regulatory-ready tech. And policy shifts that matter.

We recently had the pleasure of speaking with Dr. Marialaura Madrigal, Research Director of Medistem Panama Inc., who shared her perspectives on the growing importance of scalable cell manufacturing, the value of regulatory-ready technologies, and the opportunities emerging across the global CGT landscape.

From her experience with our 3D TableTrix™ Microcarriers and her views on China's recent 818 & 828 policies, the conversation highlights how technological innovation and regulatory progress can work together to accelerate the development of advanced therapies.

Thank you, Dr. Madrigal, for sharing your valuable insights.


01/06/2026

High DecaGiga Cell Manufacturing Masterclass successfully concluded at CytoNiche’s Beijing Headquarters, bringing together participants internationally for an intensive programme focused on the future of scalable regenerative medicine manufacturing.

As Cell & Gene Therapy continues advancing toward industrial-scale production, manufacturing is becoming just as important as scientific discovery. The ability to produce living therapies consistently, safely, and at scale will play a defining role in the future of regenerative medicine.

Throughout the programme, participants explored:
🔹 Scalable 3D cell culture technologies
🔹 Automated and closed-system manufacturing workflows
🔹 Microcarrier-based expansion strategies
🔹 Exosome harvesting and cell processing technologies
🔹 Aseptic filling and integrated manufacturing systems

Through a combination of theoretical sessions, live demonstrations, and hands-on operational training, participants gained practical insights into the evolving industrial landscape of advanced therapy manufacturing.

As the industry continues transitioning toward automation, standardisation, and scalable GMP-oriented manufacturing, workforce readiness and technical expertise will become increasingly critical across the global CGT ecosystem.

Thank you to all participants, collaborators, and team members who contributed to the success of this masterclass.

29/05/2026

Regenerative medicine is no longer limited by biology alone — manufacturing is becoming just as important.

As the CGT industry moves toward commercialization, regulators are placing greater focus on:
🔹 Manufacturing consistency
🔹 Process reproducibility
🔹 Traceability
🔹 Scalability

This is one reason why automated 3D cell manufacturing systems are gaining increasing attention across the industry.

Compared to traditional 2D culture methods, 3D manufacturing platforms may offer better scalability, reduced manual intervention, improved contamination control, and stronger GMP compatibility.

In this video, we explore why manufacturing technology could become one of the key factors shaping the future of regenerative medicine.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/21.html

Beyond innovation, progress is ultimately built on humanity, trust, and shared purpose.This Hari Raya Haji, CytoNiche ce...
27/05/2026

Beyond innovation, progress is ultimately built on humanity, trust, and shared purpose.

This Hari Raya Haji, CytoNiche celebrates the spirit of dedication, resilience, and compassion that continues to bring communities together across borders and industries.

As we continue advancing scalable cell manufacturing technologies for the future of healthcare, we remain grateful for the trust, partnerships, and collaborations that make innovation possible.

Wishing our colleagues, partners, and friends around the world a meaningful Hari Raya Haji filled with peace, reflection, and togetherness.

Selamat Hari Raya Haji from all of us at CytoNiche.

Address

1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH
Singapore
138542

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Website

Alerts

Be the first to know and let us send you an email when CytoNiche Biotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to CytoNiche Biotech:

Shortcuts

Share

Category